IVD manufacturing: lot-to-lot consistency and the instrument that locks in reagent revenue

Placing the analyser is the sales strategy

Instruments are frequently supplied under reagent rental or managed service arrangements rather than sold, with the capital recovered through consumable pricing across a multi-year contract. That structure suits laboratories, which prefer operating budget to capital, and it locks the manufacturer's revenue to the installed base. It also puts real money at risk: an instrument placed at a laboratory that under-tests, or that loses a contract, becomes a stranded asset. Manufacturers therefore underwrite placements like a finance business, and the sales organisation is measured on committed test volume rather than on instruments shipped.

Biological raw materials are the fragile input

Antibodies, enzymes and matrix materials vary between preparations in ways that affect assay behaviour, and the supplier's certificate rarely predicts how a lot will perform in a specific formulation. Incoming qualification therefore means running the material in the assay, not just checking documentation. Some inputs come from a single supplier with no realistic alternative, and some derive from biological sources with their own collection and ethical constraints. When a critical antibody clone becomes unavailable, the response is a reformulation and a revalidation, which is why diagnostics companies hold deep inventory of exactly the materials that are hardest to store.

Lot release is a laboratory operation with commercial consequences

Each finished lot must demonstrate that it performs like its predecessors: calibrators assign correct values, controls fall within expected ranges, precision and sensitivity meet claims, and stability data supports the assigned expiry. This is real analytical work occupying real laboratory capacity, and it sits between production and revenue. Laboratories notice lot-to-lot shifts immediately because their internal quality control charts move, and a shift large enough to force them to revalidate is a serious customer relations event. Manufacturers therefore build lot bridging into release, comparing every new lot against the outgoing one on real samples.

Dating and cold chain make forecasting unforgiving

Reagents have limited shelf life and most require refrigerated or frozen storage from filling to the customer's bench. Building ahead ties up capital in product that may expire; building late risks stock-outs that stop clinical testing. The planning problem is compounded by uneven demand, since screening programmes and outbreaks create surges the base plan never anticipated. Distribution adds risk of its own, because a temperature excursion in transit can invalidate a shipment that looks physically intact. Manufacturers who monitor shipping lanes and hold regional stock trade working capital for the ability to honour a contract.

Laboratory consolidation and reimbursement decide the market

Individual hospital laboratories are increasingly consolidated into networks that tender for platforms across many sites at once, so a single contract decision can move a large volume of business. Those tenders weigh menu breadth heavily: a laboratory prefers to run many tests on fewer platforms, so a manufacturer with a narrow menu loses regardless of assay quality. Reimbursement policy sits behind all of this, setting what a laboratory earns per test and therefore what it will pay for reagents. New assays without a reimbursement pathway struggle even when the clinical case is sound.

Frequently asked questions

Why does menu breadth matter so much in diagnostics tenders?

Because laboratories are optimising their whole workflow, not buying individual assays. Every additional platform on the bench means more maintenance contracts, more operator training, more quality control material and more bench space. A supplier who can cover a large share of the routine test menu on one system reduces all of that. This is why narrow specialists usually sell through partnerships with broad platform suppliers rather than competing for the core laboratory contract directly.

What typically causes a diagnostic lot to fail release?

Most commonly a shift in a critical biological raw material, showing up as calibration values drifting or controls falling outside expected ranges. Formulation and filling errors occur but are usually caught earlier. Stability results that do not support the intended dating can also block release, particularly for new products where the stability model is based on limited data. Because each of these is discovered in the laboratory after production is complete, the cost of a failed lot includes the whole manufacturing run.

Why is changing an antibody supplier a project rather than a purchase?

Because the antibody is not an interchangeable chemical. Binding characteristics, specificity and behaviour in the specific buffer system differ between clones and even between preparations, and those differences change assay performance in ways users would detect. A change therefore requires reformulation work, analytical comparison against the current product, stability data on the new configuration, and a decision on whether the change affects the performance claims made to regulators and to customers.